![Ziad Mirza](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ziad Mirza
Oprichter bij Baltimore Medical & Surgical Associates
Profiel
Ziad Mirza is the founder of Baltimore Medical & Surgical Associates.
He is currently the Medical Director of the Wound Care & Hyperbaric Unit at Greater Baltimore Medical Center and the Chief Medical Officer at Hyperheal Hyperbarics, Inc. Previously, he served as the CEO of FasTrack Pharmaceuticals, Inc. in 2010 and as an Independent Director at Innovus Pharmaceuticals, Inc. from 2012 to 2020.
Dr. Mirza holds an MBA from the University of Massachusetts and a doctorate from the American University of Beirut.
Actieve functies van Ziad Mirza
Bedrijven | Functie | Begin |
---|---|---|
Baltimore Medical & Surgical Associates | Oprichter | - |
Greater Baltimore Medical Center
![]() Greater Baltimore Medical Center Hospital/Nursing ManagementHealth Services Greater Baltimore Medical Center provides health care services. It is a nearly 310 bed hospital which also operates the Hospice of Baltimore, the Hospice of Howard County, the Gilchrist Center for Hospice Care, plus various clinics and medical offices. Greater Baltimore Medical Center was founded in 1960 and is headquartered in Baltimore, MD. | Corporate Officer/Principal | - |
Hyperheal Hyperbarics, Inc. | Hoofd Techniek/Wetenschap/O&O | 01-02-2016 |
Eerdere bekende functies van Ziad Mirza
Bedrijven | Functie | Einde |
---|---|---|
INNOVUS PHARMACEUTICALS INC | Voorzitter | 01-01-2012 |
FasTrack Pharmaceuticals, Inc.
![]() FasTrack Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology FasTrack Pharmaceuticals, Inc. is a privately-held specialty pharmaceutical company engaged in the development of innovative human therapeutic drugs including drugs to treat liver cancer and autoimmune diseases. Their lead product, PrevOnco, is a H+/K+-ATPase inhibitor, which was granted Orphan Drug Status by the FDA in August 2008. PrevOnco is currently in Phase 3 development as a potential second line therapy for patients with liver cancer. They also have an innovative pipeline of novel products for the Over-the Counter markets including Apeaz and Regia, indicated for pain relief and bleeding of the gums, respectively. | Algemeen Directeur | 01-12-2010 |
Opleiding van Ziad Mirza
University of Massachusetts | Masters Business Admin |
American University of Beirut | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 5 |
---|---|
Innovus Pharmaceuticals, Inc.
![]() Innovus Pharmaceuticals, Inc. Pharmaceuticals: OtherHealth Technology Innovus Pharmaceuticals, Inc. engages in the commercialization, licensing, and development of non-prescription medicine, and consumer care products for health and vitality, and respiratory diseases. Its products focuses in six main categories, including sexual health, pain management, general muscle health, respiratory, sleep, and diabetic care. The company was founded on January 15, 1959 and is headquartered in Englewood, CO. | Health Technology |
Baltimore Medical & Surgical Associates | |
Greater Baltimore Medical Center
![]() Greater Baltimore Medical Center Hospital/Nursing ManagementHealth Services Greater Baltimore Medical Center provides health care services. It is a nearly 310 bed hospital which also operates the Hospice of Baltimore, the Hospice of Howard County, the Gilchrist Center for Hospice Care, plus various clinics and medical offices. Greater Baltimore Medical Center was founded in 1960 and is headquartered in Baltimore, MD. | Health Services |
Hyperheal Hyperbarics, Inc. | |
FasTrack Pharmaceuticals, Inc.
![]() FasTrack Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology FasTrack Pharmaceuticals, Inc. is a privately-held specialty pharmaceutical company engaged in the development of innovative human therapeutic drugs including drugs to treat liver cancer and autoimmune diseases. Their lead product, PrevOnco, is a H+/K+-ATPase inhibitor, which was granted Orphan Drug Status by the FDA in August 2008. PrevOnco is currently in Phase 3 development as a potential second line therapy for patients with liver cancer. They also have an innovative pipeline of novel products for the Over-the Counter markets including Apeaz and Regia, indicated for pain relief and bleeding of the gums, respectively. | Health Technology |